An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Over the last nine months, four senators led by Sen. Dick Durbin (D-Ill.) have conducted an inquiry into the growing partnerships between direct-to-consumer telehealth companies and pharmaceutical ...

A weekend focused on women’s health and women’s basketball, all in Eli Lilly’s home state of Indiana? Consider that a layup ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

More than 450 fans of fashion icon Lilly Pulitzer attended events in Palm Beach, Palm Beach Gardens and West Palm Beach ...

The Eli Lilly and Company Foundation awarded a multi-year grant of up to $5.5 million to the Indianapolis Public Schools (IPS ...

Eli Lilly said on Tuesday it has begun selling vials of the lowest starter dose of its popular weight-loss drug Zepbound in the United States for $399 for a month's supply through its direct-to ...